Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.

MLA

Almhanna, Khaldoun, et al. “Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 22, no. 20, Oct. 2016, pp. 5049–57. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-15-2474.

APA

Almhanna, K., Kalebic, T., Cruz, C., Faris, J. E., Ryan, D. P., Jung, J., Wyant, T., Fasanmade, A. A., Messersmith, W., & Rodon, J. (2016). Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(20), 5049–5057. https://doi.org/10.1158/1078-0432.CCR-15-2474

Chicago

Almhanna, Khaldoun, Thea Kalebic, Cristina Cruz, Jason E Faris, David P Ryan, JungAh Jung, Tim Wyant, Adedigbo A Fasanmade, Wells Messersmith, and Jordi Rodon. 2016. “Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 22 (20): 5049–57. doi:10.1158/1078-0432.CCR-15-2474.